APA (7th ed.) Citation

N, d. G., AF, d. G., Y, W., D, K., CS, K., S, V., . . . JR, K. (2026). Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer. Breast cancer research : BCR, 28(1), . https://doi.org/10.1186/s13058-026-02245-4

Chicago Style (17th ed.) Citation

N, de Gruil, et al. "Pathway Activity Profiling Can Predict Neoadjuvant Endocrine Therapy Response in HR+ HER2- Postmenopausal Early Stage Breast Cancer." Breast Cancer Research : BCR 28, no. 1 (2026). https://doi.org/10.1186/s13058-026-02245-4.

MLA (9th ed.) Citation

N, de Gruil, et al. "Pathway Activity Profiling Can Predict Neoadjuvant Endocrine Therapy Response in HR+ HER2- Postmenopausal Early Stage Breast Cancer." Breast Cancer Research : BCR, vol. 28, no. 1, 2026, https://doi.org/10.1186/s13058-026-02245-4.